|
Wednesday, 30 July 2008 |
|
UAE. Dulsco HR Solutions, the region's largest human resource outsourcing company, has announced that it has kicked off an aggressive expansion program, as a result of a continued surge in demand for blue-collar workers to service the UAE's expanding multi-sector economy.
Recent statistics have revealed that the UAE's labour market posted a remarkable growth rate of 36.04% during the period 2001 to 2005, a figure that has been increasing even further with no signs of slowing down, creating exciting growth opportunities for Dulsco's wide range of human resource solutions. Leveraging its excellent track record and extensive industry experience, Dulsco HR Solutions has been focusing its growth strategy on various workforce-intensive sectors, particularly the blue-collar labour market, which has been a critical asset in powering the UAE's program of economic diversification in non-oil sectors. "Dulsco HR Solutions has stepped up its efforts to satiate the UAE's burgeoning demand for blue-collar workers as we are fully aware that our ability to adequately supply the manpower needs of these critical sectors will be an important contributing factor to the overall growth of the national economy. Scouring the labour market can be a daunting task for many firms; it is our objective to facilitate this process and help them optimise their staffing initiatives," said Dsouza Valerian, General Manager, Manpower Services, Dulsco HR Solutions. |
|
Read more...
|
|
|
Wednesday, 30 July 2008 |
|
It's the biggest deal of the year and a strange one at that: Roche's unsolicited bid for the remaining 44% of Genentech it didn't already own. I want to look at this model of - let's call it insourcing to go along with the popular scary word outsourcing - and see if it makes sense for anyone and Roche in particular. Added complications are of course that Roche already OWNS 56% of the outstanding shares, hence it controls the company and so forth. So why do it?
Certainly, Roche’s earnings are slowing and buying the remainder of Genentech will allow it to consolidate 100% of Genentech’s profits, not merely 56% of them. However, there is one big reason not to do the deal: this has been the most successful relationship in pharmaceutical history. Neither company would likely exist as an independent entity without it. Genentech was an acquisition waiting to happen back in 1990 when it managed to keep at least managerial independence by selling Roche 60% of its shares. Without Genentech, the Swiss giant would most likely be part of another Swiss giant, Novartis (which still owns a small stake in the pharma).
By buying Genentech Roche wants to consolidate what has become to expensive to keep independent. The deal was announced the day after the Genentech CEO Art Levinson learned about it so that doesn't speak volumes about Roche's intent to give Genentech's management a long leash. |
|
Last Updated ( Wednesday, 30 July 2008 )
|
|
Read more...
|
| |
|
|
Fax Software and Fax Services
